Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial

BACKGROUND: Nab-paclitaxel/gemcitabine (AG) and FOLFIRINOX (FFX) are promising drugs in metastatic pancreatic cancer (MPC). This study evaluated a new first-line sequential treatment (AG followed by FFX) in MPC that might overcome resistance to primary therapy and delay tumor progression. PATIENTS A...

Descripción completa

Detalles Bibliográficos
Autores principales: Assenat, E., de la Fouchardière, C., Portales, F., Ychou, M., Debourdeau, A., Desseigne, F., Iltache, S., Fiess, C., Mollevi, C., Mazard, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637474/
https://www.ncbi.nlm.nih.gov/pubmed/34837745
http://dx.doi.org/10.1016/j.esmoop.2021.100318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637474/
https://www.ncbi.nlm.nih.gov/pubmed/34837745
http://dx.doi.org/10.1016/j.esmoop.2021.100318

Ejemplares similares